Zacks Investment Research
17 Jun 2026, 22:50 UTC · 2h ago
Amgen (AMGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
17 Jun 2026, 22:50 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Amgen's projected earnings per share (EPS) for the upcoming quarter are $5.55, representing a 7.81% decrease year-over-year. — A significant projected decline in quarterly earnings typically puts downward pressure on a stock price.
-0.40Amgen is currently trading at a Forward P/E ratio of 15.65, which is a discount compared to the industry average of 21.05. — Trading at a discount to industry peers suggests the stock may be undervalued, which is generally positive for investors.
+0.30Amgen's consensus revenue estimate for the upcoming quarter is $9.44 billion, a 2.87% increase compared to the year-ago quarter. — Modest revenue growth is a positive signal, though it is offset by the projected EPS decline.
+0.20Continue reading
6 related stories
Top 1 mover · tap to explore
Amgen currently holds a Zacks Rank #3 (Hold). — A 'Hold' rating is neutral and suggests no immediate strong conviction for buying or selling.
+0.00Which stocks this story touches
The stock closed down 1.78% and projected EPS is expected to decrease by 7.81% compared to the previous year.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
2h ago
